CRID3 sodium salt

Pricing Availability   Qty
Description: Potent NLRP3 inflammasome inhibitor; inhibits IL-1β production
Alternative Names: CP-456773, MCC 950
Chemical Name: N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt
Purity: ≥98% (HPLC)
Citations (10)
Literature (1)

Biological Activity for CRID3 sodium salt

CRID3 sodium salt is a potent NLRP3 inflammasome inhibitor; closes the active conformation of NLRP3 to the inactive state. Directly interacts with the Walker B motif within the NLRP3 NACHT domain. Inhibits IL-1β, IL-18 and IL-1α production (IC50 values are 7.2, 10.3 and 12-18 nM, respectively). Selective for NLRP3 over NLRC4 inflammasome and Toll-like receptor signaling. Reduces severity of experimental autoimmune encephalomyelitis, skin inflammation and airway inflammation in mice. Also glutathione S-transferase omega 1 inhibitor. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc

Technical Data for CRID3 sodium salt

M. Wt 426.46
Formula C20H23N2NaO5S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 256373-96-3
PubChem ID 91826093
Smiles O=C(N(S(C4=CC(C(C)(O)C)=CO4)(=O)=O)[Na])NC1=C3C(CCC3)=CC2=C1CCC2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for CRID3 sodium salt

Solvent Max Conc. mg/mL Max Conc. mM
water 42.65 100
DMSO 42.65 100

Preparing Stock Solutions for CRID3 sodium salt

The following data is based on the product molecular weight 426.46. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.34 mL 11.72 mL 23.45 mL
5 mM 0.47 mL 2.34 mL 4.69 mL
10 mM 0.23 mL 1.17 mL 2.34 mL
50 mM 0.05 mL 0.23 mL 0.47 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for CRID3 sodium salt

References for CRID3 sodium salt

References are publications that support the biological activity of the product.

Laliberte et al (2003) Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1β posttranslational processing. J.Biol.Chem. 278 16567 PMID: 12624100

Coll et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat.Med. 21 248 PMID: 25686105

Gordon et al (2018) Inflammasome inhibition prevents a-synuclein pathology and dopaminergic neurodegeneration in mice. Sci.Transl.Med. 10 eaah4066 PMID: 30381407

Tapia-Abellán et al (2019) MCC950 closes the active conformation of NLRP3 to an inactive state. Nat.Chem.Biol. 15 560 PMID: 31086329

Coll et al (2019) MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat.Chem.Biol. 15 556 PMID: 31086327

If you know of a relevant reference for CRID3 sodium salt, please let us know.

Keywords: CRID3 sodium salt, CRID3 sodium salt supplier, CP456773, cytokine, release, inhibitory, drug, CRID3, Glutathione, S-transferase, omega, 1, GSTO1, inhibitors, inhibits, MCC950, nod-like, receptors, NLRP3, inflammasome, CP-456773, MCC, 950, Other, Transferases, Cytokines, Inflammasomes, 5479, Tocris Bioscience

10 Citations for CRID3 sodium salt

Citations are publications that use Tocris products. Selected citations for CRID3 sodium salt include:

Chauhan et al (2018) BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1β Maturation in Macrophages. Cell Rep 25 2354 PMID: 30485805

David A et al (2022) Interleukin 38 alleviates aortic valve calcification by inhibition of NLRP3. Proc Natl Acad Sci U S A 119 e2202577119 PMID: 36037361

Flóra et al (2022) Maternal P2X7 receptor inhibition prevents autism-like phenotype in male mouse offspring through the NLRP3-IL-1β pathway. Brain Behav Immun 101 318-332 PMID: 35065198

Eduardo et al (2021) An in vitro study of ApxI from Actinobacillus pleuropneumoniae serotype 10 and induction of NLRP3 inflammasome-dependent cell death. Vet Rec Open 8 e20 PMID: 34631111

Do you know of a great paper that uses CRID3 sodium salt from Tocris? Please let us know.

Reviews for CRID3 sodium salt

There are currently no reviews for this product. Be the first to review CRID3 sodium salt and earn rewards!

Have you used CRID3 sodium salt?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.